Skip to results
Modify your search
NARROW
1-20 of 44
Authors: Niklas Thon
Journal Article
The inconsistent terminology for the extent of resection in glioblastoma: A systematic review on 6 decades of neuro-oncological studies Get access
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 583–585, https://doi.org/10.1093/neuonc/noae254
Published: 26 December 2024
Journal Article
Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments Get access
Neuro-Oncology, Volume 27, Issue 1, January 2025, Pages 77–88, https://doi.org/10.1093/neuonc/noae208
Published: 19 November 2024
Journal Article
SURG-15. THE INCONSISTENT TERMINOLOGY FOR EXTENT OF RESECTION IN GLIOBLASTOMA: A SYSTEMATIC REVIEW ON SIX DECADES OF NEURO-ONCOLOGICAL STUDIES
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii277, https://doi.org/10.1093/neuonc/noae165.1095
Published: 11 November 2024
Journal Article
PATH-12. CLINICAL AND NEUROPATHOLOGICAL MARKERS FOR DISTINGUISHING BETWEEN IDH-MUTANT ASTROCYTOMAS OF WHO GRADE 2 AND 3
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii180, https://doi.org/10.1093/neuonc/noae165.0711
Published: 11 November 2024
Journal Article
SURG-42. THE T1/T2 RATIO IS ASSOCIATED WITH RESECTABILITY IN PATIENTS WITH IDH-MUTANT ASTROCYTOMAS CNS WHO GRADES 2 AND 3
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii283, https://doi.org/10.1093/neuonc/noae165.1121
Published: 11 November 2024
Journal Article
NIMG-48. MEASURABLE DISEASE AS BASELINE CRITERION FOR RESPONSE ASSESSMENT IN GLIOBLASTOMA TRIALS – A COMPARATIVE STUDY OF MRI-BASED (RANO 2.0) VERSUS PET-BASED (PET RANO 1.0) ASSESSMENT
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii206, https://doi.org/10.1093/neuonc/noae165.0812
Published: 11 November 2024
Journal Article
SURG-19. THE SYNDROME OF THE SUPPLEMENTARY MOTOR AREA: CLINICAL COURSE AND PREDICTORS OF OUTCOME AFTER RESECTION OF PREMOTOR LESIONS
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii277–viii278, https://doi.org/10.1093/neuonc/noae165.1099
Published: 11 November 2024
Journal Article
EXTH-13. COMBINED ANTI-ANGIOGENIC TREATMENT TO INCREASE INTRATUMORAL PERSISTENCE OF CAR T-CELLS IN LUNG CANCER BRAIN METASTASES
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii239, https://doi.org/10.1093/neuonc/noae165.0944
Published: 11 November 2024
Journal Article
PATH-27. MOLECULAR, IMAGING, AND SURVIVAL MANIFESTATIONS IN MOLECULAR GLIOBLASTOMAS: INSIGHTS FROM A MULTI-NATIONAL STUDY
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii184, https://doi.org/10.1093/neuonc/noae165.0726
Published: 11 November 2024
Journal Article
SURG-21. DEVELOPMENT AND VALIDATION OF A CLINICAL RISK SCORE FOR POSTOPERATIVE OUTCOME IN NEWLY DIAGNOSED GLIOBLASTOMA: A REPORT OF THE RANORESECT GROUP
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii278, https://doi.org/10.1093/neuonc/noae165.1101
Published: 11 November 2024
Journal Article
CTNI-65. DETERMINANTS OF LONG-TERM SURVIVAL IN PATIENTS WITH IDH-MUTANT GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii112, https://doi.org/10.1093/neuonc/noae165.0432
Published: 11 November 2024
Journal Article
NIMG-53. MRI-BASED RADIOMICS FOR DIFFERENTIATION BETWEEN PERIFOCAL EDEMA AND NON-CONTRAST-ENHANCING GLIOBLASTOMA FOCI
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii207, https://doi.org/10.1093/neuonc/noae165.0817
Published: 11 November 2024
Journal Article
Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group
Neuro-Oncology, noae231, https://doi.org/10.1093/neuonc/noae231
Published: 04 November 2024
Journal Article
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group
Neuro-Oncology, Volume 26, Issue 3, March 2024, Pages 584–586, https://doi.org/10.1093/neuonc/noad237
Published: 02 January 2024
Journal Article
EXTH-25. IN VIVO TWO-PHOTON TUMOR IMAGING IN AN ORTHOTOPIC MEDULLOBLASTOMA MOUSE MODEL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v229, https://doi.org/10.1093/neuonc/noad179.0878
Published: 10 November 2023
Journal Article
EXTH-73. IN VIVO EFFECTS OF EPCAM-DIRECTED CAR T CELLS IN COMBINATION WITH PD-1 CHECKPOINT BLOCKADE IN LUNG CANCER BRAIN METASTASIS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v241, https://doi.org/10.1093/neuonc/noad179.0926
Published: 10 November 2023
Journal Article
CTNI-11. THE VALUE OF STEREOTACTIC BIOPSY OF PRIMARY AND RECURRENT BRAIN METASTASES IN THE ERA OFPRECISION MEDICINE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v75, https://doi.org/10.1093/neuonc/noad179.0293
Published: 10 November 2023
Journal Article
INNV-06. SIGNIFICANCE OF MOLECULAR DIAGNOSTICS FOR THERAPEUTIC DECISION-MAKING IN RECURRENT GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v157, https://doi.org/10.1093/neuonc/noad179.0596
Published: 10 November 2023
Journal Article
CTNI-31. TREATMENT BENEFIT IN PATIENTS AGED 80 YEARS OR OLDER WITH BIOPSY-PROVEN AND NON-RESECTED GLIOBLASTOMA IS DEPENDENT ON MGMT PROMOTER METHYLATION STATUS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v81, https://doi.org/10.1093/neuonc/noad179.0313
Published: 10 November 2023
Journal Article
Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group
Neuro-Oncology, Volume 26, Issue 1, January 2024, Pages 166–177, https://doi.org/10.1093/neuonc/noad160
Published: 04 September 2023
